Related Experiment Video
Updated: Jun 28, 2026
07:48
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 2, 2013
Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification,
Roger Li1, Patrick J Hensley2, Marko Babjuk3
1Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA.
European Urology Oncology
|October 11, 2025
Summary
New guidelines define intermediate-risk non-muscle-invasive bladder cancer (NMIBC) and recommend risk-stratified management, including deintensification for select patients. These recommendations aim to improve patient care and clinical trial design for NMIBC.
Area of Science:
- Urology
- Oncology
Background:
- Intermediate-risk non-muscle-invasive bladder cancer (IR-NMIBC) is a complex condition requiring standardized definitions.
- Effective management and clinical trial development depend on clear risk stratification.
Purpose of the Study:
- To establish consensus recommendations for the definition and management of IR-NMIBC.
- To guide clinical care and the design of clinical trials for IR-NMIBC.
Main Methods:
- A global committee of bladder cancer experts convened.
- Recommendations were drafted by working groups, reviewed literature, and refined using a modified Delphi process with International Bladder Cancer Group (IBCG) members.
- Final recommendations achieved over 75% agreement.
Main Results:
- The IBCG recommends including only low-grade (LG; G1 and G2) tumors in the IR-NMIBC category, stratified by the IBCG IR-NMIBC risk scoring system.
- Therapeutic deintensification (active surveillance, office-based ablation) is appropriate for select IR-NMIBC patients.
- Recommendations address reducing morbidity, optimizing perioperative chemotherapy, and risk-stratifying adjuvant intravesical treatments.
Conclusions:
- The IBCG consensus provides practical guidance for the clinical management of IR-NMIBC.
- These recommendations offer a framework for designing future clinical trials, emphasizing patient-reported outcomes and risk-stratified controls.
